Mutated KRAS is consideredone of the key targetsin cancer drug discovery.1 The successof covalent inhibition of KRAS(G12C) to its switch-II pocket (SII-P)(reviewed in2,3) is exemplified by the first clinicallyapproved KRAS-targeting drugs sotorasib and adagrasib. The gene discussed is KRAS; the disease is cancer.